Showing results (291-300 of 470) with videos related to
Sort By:
Pageof 47
Cancer Research|December 5, 2022
Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast CancerLixuan Wei, Huanyao Gao, Jia Yu, et al.JAMA Oncology|April 26, 2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysisYucai Wang, Shouhao Zhou, Fang Yang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT GroupDaniel J Sargent, Smitha Patiyil, Greg Yothers, et al.JAMA Network Open|February 3, 2023
Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010Carolyn M Larsen, Mariana Garcia Arango, Harika Dasari, et al.Clinical Colorectal Cancer|December 12, 2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C StudyManish A Shah, Takayuki Yoshino, Niall C Tebbutt, et al.The Lancet. Oncology|April 17, 2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Takayuki Yoshino, Allen Lee Cohn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2016
Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints DatabaseWinson Y Cheung, Lindsay A Renfro, David Kerr, et al.Human Immunology|June 18, 2020
Concordance between predicted HLA type using next generation sequencing data generated for non-HLA purposes and clinical HLA typeAnn M Moyer, Brian Dukek, Patti Duellman, et al.Breast Cancer Research and Treatment|October 21, 2024
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108Vered Stearns, Anne ONeill, Bryan P Schneider, et al.Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.Pageof 47